Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020113063 - SINGLE DOMAIN ANTIBODIES AGAINST CLL-1

Publication Number WO/2020/113063
Publication Date 04.06.2020
International Application No. PCT/US2019/063691
International Filing Date 27.11.2019
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/18 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/46 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
C07K 19/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
C12N 15/09 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
CPC
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Applicants
  • ALETA BIOTHERAPEUTICS INC. [US]/[US]
Inventors
  • LOBB, Roy
  • RENNERT, Paul
Agents
  • VETTER, Michael L.
  • ADAMS, Melissa M.
  • ADATO, Ronen
  • AUGST, Alexander D.
  • BUTEAU, Kristen C.
  • BYCHOWSKI, Meaghan E.
  • D'AMATO, Erica M.
  • DAUKSS, Dana M.
  • FLYNN, Peter A.
  • HAULBROOK, William R.
  • JARRELL, Brenda Herschbach
  • JUDA, Cristin E.
  • LI, Xiaodong
  • LI, Bin
  • LYON, Charles E.
  • MA, Longle
  • MEDINA, Rolando
  • MONROE, Margo R.
  • PACE, Nicholas J.
  • REARICK, John P.
  • REESE, Brian E.
  • SCHMITT, Michael
  • SCHONEWALD, Stephanie L.
  • SHINALL, Michael A.
  • SHORE, David E.
  • SMITH, Maria C.
  • SUBRAMANIAN, Sowmya
  • SUH, Su Kyung
  • TSE, Janet M.
  • VRABLIK, Tracy L.
  • ZHANG, jIALAN
Priority Data
62/774,02530.11.2018US
62/780,09214.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SINGLE DOMAIN ANTIBODIES AGAINST CLL-1
(FR) ANTICORPS À DOMAINE UNIQUE CIBLANT CLL-1
Abstract
(EN)
Antibodies that specifically bind to CLL-1 are described, as well as methods of making and using such antibodies. In one aspect, the present disclosure provides, among other things, antibodies, or antigen binding fragments thereof, that bind (e.g., selectively bind) CLL-1, compositions useful for binding CLL-1, and methods for treating disease comprising administration of such antibodies, or antigen binding fragments thereof.
(FR)
L'Invention concerne des anticorps qui se lient particulièrement à LLC-1, ainsi que des procédés de fabrication et des méthodes d'utilisation de tels anticorps. Selon un de ses aspects, la présente invention concerne, entre autres, des anticorps, ou des fragments de liaison à l'antigène de ceux-ci, qui se lient (par exemple qui se lient sélectivement) à CLL-1, des compositions qui s'utilisent pour lier à CLL-1, et des méthodes pour traiter des maladies comprenant l'administration de tels anticorps ou de fragments de liaison à l'antigène de ceux-ci.
Latest bibliographic data on file with the International Bureau